Radiotherapy and concurrent radiochemotherapy for rectal cancer

Area of Science:

• Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Adjuvant radiotherapy, with or without chemotherapy, is a common treatment for rectal cancer.
• Postoperative radiochemotherapy improved local control and survival for locally advanced rectal cancer (TNM stages II and III) compared to surgery alone or surgery plus irradiation.
• Preoperative radiotherapy in Europe demonstrated lower local failure rates compared to surgery alone, with a meta-analysis confirming improved local control and survival.

Purpose of the Study:

• To question the current standard monolithic treatment approaches for rectal cancer.
• To evaluate the necessity of standardized postoperative radiochemotherapy or preoperative radiotherapy for all patients with resectable rectal cancer.

Main Methods:

• Review of existing randomized studies and meta-analyses on preoperative and postoperative radiotherapy for rectal cancer.
• Consideration of recent reports on outcomes with improved surgical techniques, such as total mesorectal excision.

Main Results:

• Postoperative radiochemotherapy significantly improved local control and overall survival in locally advanced rectal cancer.
• Preoperative radiotherapy combined with surgery significantly improved local control and overall survival compared to surgery alone.
• Recent advancements in surgical techniques, including total mesorectal excision, have resulted in exceptionally low local failure rates.

Conclusions:

• The universal application of either postoperative radiochemotherapy or preoperative radiotherapy for all rectal cancer patients needs critical reassessment.
• The effectiveness of improved surgical techniques challenges the necessity of current standardized radiotherapy protocols for all stages and treatment goals.